Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status

AIDS Research and Human Retroviruses

Volumn 24, Issue 10, 2008, Pages 1255-1262

  Shikuma, Cecilia M ^a,c   Gerschenson, Mariana ^a   Chow, Dominic ^a   Libutti, Daniel E ^a   Willis, John H ^b   Murray, James ^b   Capaldi, Roderick A ^b   Marusich, Michael ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b MitoSciences Inc   (United States)

^c Leahi Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; LIPOATROPHY; MALE; OXIDATIVE PHOSPHORYLATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT;

ADULT; DNA, MITOCHONDRIAL; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; IMMUNOASSAY; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; OXIDATIVE PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEINS; STATISTICS AS TOPIC; SUBCUTANEOUS FAT;

EID: 53849148985     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0262     Document Type: Article

References (43)

1. Duran S, Saves M, Spire B, et al.: Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001;15:2441-2244.
2. Ammassari A, Antinori A, Cozzi-Lepri A, et al.: Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002;31(Suppl. 3):S140-144.
3. Duran S, Spire B, Raffi F, et al.: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001;2:38-45.
4. Saint-Marc T, Partisani M, Poizot-Martin I, et al.: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
5. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, and Gelato MC: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-321.
6. Vigouroux C, Maachi M, Nguyen TH, et al.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17:1503-1511.
7. Shikuma CM, Hu N, Milne C, et al.: Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-1809.
8. Mallon PW, Miller J, Cooper DA, and Carr A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17:971-979.
9. Mallal SA, John M, Moore CB, James IR, and McKinnon EJ: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-1316.
10. Moyle G: Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antiviral Ther 2005;10(Suppl. 2):M47-52.
11. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, and Koopmans PP: Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998;12:1735-1744.
12. Nolan D, Hammond E, Martin A, et al.: Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-1338.
13. Gerschenson M, Shiramizu B, LiButti DE, and Shikuma CM: Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antiviral Ther 2005;10(Suppl. 2):M83-89.
14. Walker UA, Bickel M, Lutke Volksbeck SI, et al.: Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002;29:117-121.
15. Maagaard A, Holberg-Petersen M, Kvittingen EA, Sandvik L, and Bruun JN: Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients. HIV Med 2006;7:53-58.
16. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, and Wesselingh SL: Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002;30:271-277.
17. van der Valk M, Casula M, Weverlingz GJ, et al.: Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antiviral Ther 2004;9:385-393.
18. Cherry CL, Nolan D, James IR, et al.: Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 2006;42:435-440.
19. Marusich MF, Robinson BH, Taanman JW, et al.: Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fibroblasts: A comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome. Biochim Biophys Acta 1997;1362:145-159.
20. Janes MS, Hanson BJ, Hill DM, et al.: Rapid analysis of mitochondrial DNA depletion by fluorescence in situ hybridization and immunocytochemistry: Potential strategies for HIV therapeutic monitoring. J Histochem Cytochem 2004;52:1011-1018.
21. Mallon PW, Unemori P, Sedwell R, et al.: In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005;191:1686-1696.
22. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, and Will Y: Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro 2007;21:902-911.
23. Murray J, Zhang B, Taylor SW, et al.: The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification. J Biol Chem 2003;278:13619-13622.
24. Murray J, Schilling B, Row RH, et al.: Small scale immunopurification of cytochrome c oxidase for a high throughput, multiplexing analysis of enzyme activity, and amount. Biotechnol Appl Biochem 2007;48(Pt. 4):167-178.
25. Murray J, Yonally S, Aggeler R, Marusich MF, and Capaldi RA: Focused proteomics: Towards a high throughput monoclonal antibody-based resolution of proteins for diagnosis of mitochondrial diseases. Biochim Biophys Acta 2004;1659:206-211.
26. Shiramizu B, Shikuma KM, Kamemoto L, et al.: Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003;32:370-374.
27. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-275.
28. Tien PC, Barron Y, Justman JE, et al.: Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS 2007;21:297-305.
29. Buffet M, Schwarzinger M, Amellal B, et al.: Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol 2005;33:60-64.
30. Galluzzi L, Pinti M, Guaraldi G, et al.: Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy. Antiviral Ther 2005;10(Suppl. 2):M91-99.
31. McComsey GA, Paulsen DM, Lonergan JT, et al.: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005;19:15-23.
32. Jones SP, Qazi N, Morelese J, et al.: Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005;40:565-572.
33. Hammond E, Nolan D, James I, Metcalf C, and Mallal S: Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004;18:815-817.
34. van der Valk M, Gisolf EH, Reiss P, et al.: Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15:847-855.
35. Haubrich R, Riddler S, DiRienzo G, Komarow L, Powderly W, Garren K, George T, Rooney J, Mellors J, Havlir D, and the ACTG 5142 Study Team: Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
36. Giralt M, Domingo P, Guallar JP, et al.: HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. Antiviral Ther 2006;11:729-740.
37. John M, Moore CB, James IR, et al.: Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-723.
38. Brinkman K: Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000;31:167-169.
39. Cossarizza A, Riva A, Pinti M, et al.: Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antiviral Ther 2003;8:315-321.
40. McComsey G, Tan DJ, Lederman M, Wilson E, and Wong LJ: Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002;16:513-518.
41. Chiappini F, Teicher E, Saffroy R, et al.: Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004;84:908-914.
42. Simpson DM, Kitch D, Evans SR, et al.: HIV neuropathy natural history cohort study: Assessment measures and risk factors. Neurology 2006;66:1679-1687.
43. Miro O, Lopez S, Pedrol E, et al.: Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antiviral Ther 2003;8:333-338.